Hair loss is emerging as a possible side effect of GLP-1 drugs. A large BMJ study found the overall risk is small but higher than with some other diabetes medicines.
- GLP-1 users had a 37% higher hair loss risk than SGLT-2 inhibitor users, although the overall risk remained low
- Most cases involved temporary, non-scarring hair loss linked to rapid weight loss and nutritional changes
- Experts recommend maintaining good nutrition and consulting a doctor rather than stopping GLP-1 treatment
Weight loss drugs called GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, are transforming the treatment of obesity and type 2 diabetes by improving blood sugar control and promoting substantial weight loss.
According to a large study published in The BMJ, adults with type 2 diabetes who started GLP-1 receptor agonists were more likely to develop alopecia than those taking SGLT-2 inhibitors or DPP-4 inhibitors (1✔ ✔Trusted Source
Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation
).
The increase was statistically significant, but the researchers stressed that the overall chance of developing hair loss remained low. Most reported cases involved non-scarring alopecia, a form of hair loss in which the follicles remain healthy, making future hair regrowth possible.
The findings also support earlier evidence summarized in a Science Progress systematic review, which suggests that semaglutide and tirzepatide are the GLP-1 medicines most often linked with temporary hair shedding (2✔ ✔Trusted Source
GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
However, experts note that current research cannot yet confirm whether the medicines themselves are responsible or whether the hair loss is mainly related to the rapid weight loss they produce.
Advertisement
Do GLP-1 Drugs Really Increase Hair Loss Risk?
According to the study, researchers analyzed electronic health records from nearly 40,000 adults with type 2 diabetes who started GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors between 2019 and 2024.
After accounting for factors such as age, body weight, and existing health conditions, they found a modest increase in hair loss among GLP-1 users compared with the other two drug groups.
However, the overall risk remained low, and the study could not prove that GLP-1 drugs directly caused the hair loss.
A Science Progress systematic review also found that semaglutide and tirzepatide were the GLP-1 drugs most frequently linked with hair loss.
However, researchers noted that more high-quality studies are needed to determine whether the medications themselves or rapid weight loss are primarily responsible.
The table below summarizes the key findings from the study and supporting evidence.
|
Aspect |
Study Finding |
Why It Matters |
|
Study population |
Nearly 40,000 adults with type 2 diabetes who started GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors between 2019 and 2024 |
One of the largest real-world studies examining hair loss risk with GLP-1 medicines. |
|
Comparison with SGLT-2 inhibitors |
GLP-1 users had a 37% higher risk of developing alopecia. |
The increase was statistically significant, but the overall chance of hair loss remained low. |
|
Comparison with DPP-4 inhibitors |
GLP-1 users had a 68% higher risk of alopecia. |
Similar findings across two comparison groups strengthen the observed association. |
|
Nature of hair loss |
Most cases involved non-scarring alopecia (type of hair loss). |
Hair follicles remain intact, so the condition is often temporary and reversible. |
|
Supporting evidence |
A Science Progress review also found semaglutide and tirzepatide to be the GLP-1 drugs most frequently associated with hair loss. |
The BMJ findings are consistent with earlier published evidence. |
|
Study interpretation |
The study identified an association, not a direct cause-and-effect relationship. |
Rapid weight loss, reduced calorie intake, nutritional deficiencies, and other health factors may also contribute to hair loss. |
Advertisement
Why Might GLP-1 Drugs Trigger Hair Loss?
The study found a small increase in hair loss among people taking GLP-1 receptor agonists but could not confirm that the medicines directly caused it.
Instead, researchers believe several factors—including rapid weight loss, reduced calorie intake, and nutritional deficiencies—may temporarily disrupt the normal hair growth cycle.
Evidence from multiple expert sources points to telogen effluvium, a temporary and reversible form of hair shedding, as the most likely explanation.
Here’s how different expert sources explain the possible reasons behind GLP-1-related hair loss:
Advertisement
What Different Sources Say About GLP-1-Related Hair Loss
|
Source |
Main Finding |
Key Takeaway |
|
The BMJ |
Hair loss may be linked to rapid weight loss, reduced calorie intake, and nutritional changes rather than the medicines themselves. |
The study found an association, not proof that GLP-1 drugs directly cause hair loss. |
|
Science Progress Review |
Telogen effluvium was the most common explanation, with semaglutide and tirzepatide showing the strongest association. |
Hair shedding is usually temporary and may improve once the trigger resolves. |
|
Harvard Health Publishing (3✔ ✔Trusted Source Study: Taking GLP-1 drugs may increase risk of key nutrient deficiencies ) |
GLP-1 users may develop deficiencies in vitamin D, iron, B vitamins, and other nutrients because they eat less. |
Monitoring nutritional status during treatment may help reduce the risk. |
|
American Academy of Dermatology (AAD) (4✔ ✔Trusted Source How can GLP-1 drugs affect my skin, hair, and nails? ) |
Hair thinning is most likely caused by rapid weight loss and lower intake of protein and nutrients. |
A balanced diet and dermatologist guidance can support recovery. |
|
Cleveland Clinic (5✔ ✔Trusted Source Can Ozempic Cause Hair Loss? ) |
Rapid weight loss places the body under stress, causing nutrients to be redirected away from hair growth. |
Hair usually regrows after weight stabilizes and nutritional deficiencies are corrected. |
Who Is Most Likely to Experience Hair Loss While Taking Ozempic or Mounjaro?
Current evidence suggests that hair loss is more likely in people who lose weight rapidly, especially during the first year of GLP-1 treatment. The overall risk remains low, and most cases are temporary.
People who may be at higher risk include:
- People experiencing rapid or significant weight loss
- Those taking higher-dose GLP-1 medicines, particularly semaglutide or tirzepatide
- Women, who reported hair loss more often in current studies
- People with low protein intake or deficiencies in iron, zinc, vitamin D, and B vitamins
- Individuals with existing nutritional deficiencies or other conditions that affect hair growth
If hair loss occurs, it usually follows a predictable timeline. Here’s what researchers and experts have observed.
What to Expect if Hair Loss Occurs After Starting GLP-1 Drugs
|
Stage |
What Usually Happens |
|
First few weeks |
Appetite decreases and weight loss begins after starting treatment. |
|
Around 2–3 months |
Hair shedding may become noticeable as more hair follicles enter the resting (telogen) phase. |
|
3–6 months |
Shedding often slows as the body adapts and nutritional status improves. |
|
6–12 months |
New hair gradually grows back once weight stabilises and the trigger is resolved. |
|
When to seek medical advice |
See a doctor if hair loss is severe, patchy, continues for several months, or is accompanied by other symptoms. |
Can Hair Loss Be Prevented While Taking GLP-1 Drugs?
Although there is no guaranteed way to prevent hair loss, experts say it may be reduced by maintaining good nutrition, avoiding rapid weight loss, and addressing nutrient deficiencies early.
Since most cases are linked to temporary metabolic and nutritional changes rather than permanent follicle damage, early intervention may help limit hair shedding.
Experts recommend:
- Eat enough protein and include foods rich in iron, zinc, vitamin D, and B vitamins to support healthy hair growth.
- Avoid rapid weight loss by following your prescribed treatment plan and avoiding severe calorie restriction.
- Monitor nutritional status, especially if you are losing weight quickly or eating much less than usual.
- Stay hydrated and maintain a balanced diet throughout treatment.
- Consult a dermatologist if hair shedding becomes persistent or severe. Treatments such as topical minoxidil may be considered after ruling out other causes.
- Do not stop Ozempic, Mounjaro, or other GLP-1 medicines on your own. Speak with your healthcare provider, who can assess nutritional deficiencies, review your treatment plan, and recommend appropriate management while allowing you to continue benefiting from therapy.
Should Hair Loss Make You Stop Taking Ozempic or Mounjaro?
For most people, the answer is no. The BMJ study found that while GLP-1 drugs were linked to a slightly higher risk of hair loss, the overall risk remained low, and the benefits of these medicines generally outweigh this potential side effect.
Experts agree that GLP-1-related hair loss is usually temporary and reversible.
Rather than stopping treatment, patients should consult their healthcare provider or a dermatologist to identify possible causes, such as telogen effluvium or nutritional deficiencies, and receive appropriate treatment.
Frequently Asked Questions
Q: Can Ozempic and Mounjaro really cause hair loss?
A: Yes, a large BMJ study found that GLP-1 drugs were linked to a slightly higher risk of temporary, non-scarring hair loss. However, the overall risk remained low.
Q: Why does hair loss happen with GLP-1 drugs?
A: Experts believe rapid weight loss, reduced calorie intake, and nutrient deficiencies are more likely to trigger hair shedding than the medicines directly.
Q: Is hair loss from Ozempic or Mounjaro permanent?
A: In most cases, no. The hair loss is usually temporary and improves once weight stabilises and nutritional deficiencies are corrected.
Q: Who is more likely to experience hair loss?
A: People who lose weight quickly, take higher doses of GLP-1 drugs, or have low protein, iron, zinc, vitamin D, or B-vitamin levels may have a higher risk.
Q: Can I reduce my risk of hair loss while taking GLP-1 medicines?
A: Yes. Eating enough protein, maintaining a balanced diet, staying hydrated, and correcting nutrient deficiencies may help support healthy hair growth.
Q: Should I stop taking Ozempic or Mounjaro if my hair starts falling out?
A: No. Do not stop your medication without speaking to your doctor. They can identify the cause of hair loss and recommend appropriate treatment while you continue therapy.
Q: How long does GLP-1-related hair loss usually last?
A: Hair shedding often begins a few months after starting treatment and usually improves within 3 to 6 months after weight stabilises, although recovery can vary from person to person.
References:
- Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation – (https://www.bmj.com/content/394/bmj-2026-100077)
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling – (https://journals.sagepub.com/doi/full/10.1177/00368504261444578)
- Study: Taking GLP-1 drugs may increase risk of key nutrient deficiencies – (https://www.health.harvard.edu/diet-and-nutrition/study-taking-glp-1-drugs-may-increase-risk-of-key-nutrient-deficiencies)
- How can GLP-1 drugs affect my skin, hair, and nails? – (https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effects)
- Can Ozempic Cause Hair Loss? – (https://health.clevelandclinic.org/does-ozempic-cause-hair-loss)
Source-Medindia